[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643571":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":49,"responsibleParty":188,"collaborators":190,"id":199,"slug":44,"hasResults":200,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":206,"sex":207,"minAge":208,"maxAge":44,"enrollmentInfo":209,"targetDuration":44,"studyType":212,"phases":213,"briefSummary":215,"conditions":216,"keywords":220,"overallStatus":226,"whyStopped":44,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":236},{"fullName":5,"class":6},"Montefiore Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment As Usual (TAU)","ACTIVE_COMPARATOR","Participants enrolled before the intervention is implemented at each syringe service program (SSP) will receive standard of care, consisting of referral to community-based buprenorphine treatment providers. SSP staff will offer information and referral support but will not provide on-site buprenorphine treatment or prescribing.",[13],"Other: Standard of Care Referral",{"label":15,"type":16,"description":17,"interventionNames":18},"Low-threshold Buprenorphine (LTB)","EXPERIMENTAL","After implementation at each SSP site, participants will have access to on-site, low-threshold buprenorphine treatment integrated into SSP services. This model focuses on minimizing barriers to treatment initiation and retention and includes , flexible policies and procedures and collaboration with a peer outreach worker.",[19],"Behavioral: Low Threshold Buprenorphine",[21,27],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Standard of Care Referral","During the pre-implementation phase, SSP staff will refer participants with opioid use disorder to external community providers for buprenorphine treatment. Services offered include information, referral assistance, and linkage to care, but buprenorphine will not be initiated or managed at the SSP site.",[9],[26],"TAU",{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"BEHAVIORAL","Low Threshold Buprenorphine","During the post-implementation phase, SSPs will implement a low-threshold model of care for buprenorphine treatment. This model includes:\n\nLow barrier to entry\n\nFlexible scheduling and follow-up procedures\n\nRisk reduction counseling\n\nCollaboration with a peer outreach worker\n\nTraining and technical assistance for SSP staff and clinicians to deliver care in non-traditional, low-barrier settings\n\nThis intervention focuses on implementing and evaluating a service delivery model to expand access to medication for opioid use disorder within SSPs.",[15],[33],"LTB",[35],{"name":36,"affiliation":37,"role":38},"Aaron D Fox, MD, MS","Albert Einstein College of Medicine","PRINCIPAL_INVESTIGATOR",[40,46],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Megan M Ghiroli","CONTACT","12036068136",null,"mghiroli@montefiore.org",{"name":36,"role":42,"phone":47,"phoneExt":44,"email":48},"718-920-7173","adfox@montefiore.org",[50,69,84,100,117,134,153,172],{"facility":51,"status":44,"city":52,"state":53,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Community Health Project Los Angeles (CHPLA)","Los Angeles","California","90029","United States",{"type":57,"coordinates":58},"Point",[59,60],-118.24368,34.05223,{"lat":60,"lon":59},[63,67],{"name":64,"role":42,"phone":65,"phoneExt":44,"email":66},"Site PI","323-380-5469","info@chpla.org",{"name":68,"role":38,"phone":44,"phoneExt":44,"email":44},"Amanda Cowan, MSc",{"facility":70,"status":44,"city":71,"state":72,"zip":73,"country":55,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"HIPS","Washington D.C.","District of Columbia","20002",{"type":57,"coordinates":75},[76,77],-77.03637,38.89511,{"lat":77,"lon":76},[80],{"name":81,"role":42,"phone":82,"phoneExt":44,"email":83},"Phyllis Bijole","202-834-3289","phyllis@hips.org",{"facility":85,"status":44,"city":86,"state":87,"zip":88,"country":55,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"CARPBR\u002FBe Safe Syringe Program","Baton Rouge","Louisiana","70806",{"type":57,"coordinates":90},[91,92],-91.18747,30.44332,{"lat":92,"lon":91},[95,98],{"name":64,"role":42,"phone":96,"phoneExt":44,"email":97},"225-775-7988","gjvar.carpbr@gmail.com",{"name":99,"role":38,"phone":44,"phoneExt":44,"email":44},"Gjvar Payne",{"facility":101,"status":44,"city":102,"state":103,"zip":104,"country":55,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Harm Reduction Sisters","Duluth","Minnesota","55805",{"type":57,"coordinates":106},[107,108],-92.10658,46.78327,{"lat":108,"lon":107},[111,115],{"name":112,"role":42,"phone":113,"phoneExt":44,"email":114},"Jack Research Coordinator","218-206-6482","jack@harmreductionsisters.org",{"name":116,"role":38,"phone":44,"phoneExt":44,"email":44},"Sue Purchase",{"facility":118,"status":44,"city":119,"state":120,"zip":121,"country":55,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Alianza of New Mexico","Roswell","New Mexico","88203",{"type":57,"coordinates":123},[124,125],-104.52491,33.39437,{"lat":125,"lon":124},[128,132],{"name":129,"role":42,"phone":130,"phoneExt":44,"email":131},"Ryan Nix Site PI","575-623-1995","ryan.nix@alianzanm.org",{"name":133,"role":38,"phone":44,"phoneExt":44,"email":44},"Ryan Nix",{"facility":135,"status":44,"city":136,"state":137,"zip":138,"country":55,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"HIV Alliance","Grants Pass","Oregon","97526",{"type":57,"coordinates":140},[141,142],-123.33067,42.43933,{"lat":142,"lon":141},[145,149,150],{"name":146,"role":42,"phone":147,"phoneExt":44,"email":148},"Harmony Beckett","541-342-5088","hbeckett@allianceor.org",{"name":146,"role":38,"phone":44,"phoneExt":44,"email":44},{"name":151,"role":152,"phone":44,"phoneExt":44,"email":44},"Michaela Starr O'Leary","SUB_INVESTIGATOR",{"facility":154,"status":44,"city":155,"state":156,"zip":157,"country":55,"cosmosGeoPoint":158,"geoPoint":162,"contacts":163},"Challenges, Inc\u002FPrisma Health","Greenville","South Carolina","29605",{"type":57,"coordinates":159},[160,161],-82.39401,34.85262,{"lat":161,"lon":160},[164,168,170],{"name":165,"role":42,"phone":166,"phoneExt":44,"email":167},"Liam Diaz, MPH","864-915-2528","Liam.Diaz@prismahealth.org",{"name":169,"role":152,"phone":44,"phoneExt":44,"email":44},"Marc Burrows, MSW, LMSW, CPSS",{"name":171,"role":38,"phone":44,"phoneExt":44,"email":44},"Alain Litwin, MD",{"facility":173,"status":44,"city":174,"state":175,"zip":176,"country":55,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"Vivent Health","Milwaukee","Wisconsin","53212",{"type":57,"coordinates":178},[179,180],-87.90647,43.0389,{"lat":180,"lon":179},[183,186],{"name":64,"role":42,"phone":184,"phoneExt":44,"email":185},"800-359-9272","ctgov.research@viventhealth.org",{"name":187,"role":38,"phone":44,"phoneExt":44,"email":44},"Mikaela Becker",{"type":189,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR",[191,194,196],{"name":192,"class":193},"National Institute on Drug Abuse (NIDA)","NIH",{"name":195,"class":6},"New York University",{"name":197,"class":198},"The Emmes Company, LLC","INDUSTRY","100643571",false,"NCT07631598","Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses","Buprenorphine Implementation at Syringe Services Programs To Reduce Overdoses: A Type 1 Hybrid Effectiveness-Implementation Trial","BISTRO","Inclusion Criteria:\n\n1. ≥ 18 years old;\n2. Meet DSM-5 criteria for moderate or severe OUD;\n3. Interest in receiving buprenorphine treatment;\n4. Speaks English or Spanish;\n5. Currently an SSP client at the time of enrollment;\n6. Ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Current use of prescribed opioid agonist treatment, as assessed by self-report, at the time of enrollment;\n2. Unstable mental health or medical condition that requires an immediate clinical evaluation or higher level of care;\n3. Allergy to buprenorphine;\n4. Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law. or have pending legal action that could prevent participation on study activities.",true,"ALL","18 Years",{"count":210,"type":211},512,"ESTIMATED","INTERVENTIONAL",[214],"NA","This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms.\n\nThe study compares two ways of connecting people to treatment:\n\nReferral to a community treatment provider (usual care before the new program begins).\n\nOnsite, low-threshold buprenorphine treatment at the SSP, which allows participants to start medication quickly and without having to establish care at another provider.\n\nParticipants will be adults who have opioid use disorder and are SSP clients. Each SSP will begin offering the new onsite buprenorphine program at different times during the study. Researchers will collect information before and after the new program begins to see how it affects treatment engagement and health outcomes.\n\nThe study will also examine how easy or difficult it is for SSPs to start and run the new program, how acceptable it is to staff and participants, and whether it is cost-effective.\n\nThe overall goal is to find better ways to expand access to life-saving opioid treatment in community-based settings.",[217,218,219],"Opioid Use Disorder","Opioid Use Disorder, Severe","Opioid Use Disorder, Moderate",[221,222,223,224,225],"Buprenorphine","Overdose Prevention","Low-Threshold Treatment","Community-Based Treatment","Medication for Opioid Use Disorder","NOT_YET_RECRUITING","2026-06-19",{"date":229,"type":230},"2026-06-23","ACTUAL",{"date":232,"type":211},"2026-08-10",{"date":234,"type":211},"2028-06",{"name":5,"class":6},8]